Eagle Health Investments LP: NATERA (NTRA): Quarterly 13F Position History
As of Q1 2026, Eagle Health Investments LP reported 121,877 shares of NATERA (NTRA), worth $24.4M and representing 5.1% of its 13F equity book. Quarter-over-quarter share count change: 61,387 (-33.5%) . The position first appeared in Q4 2020 and has been disclosed across 22 13F-HR filings in Pactolio's tracked window.
- 121,877Shares Held (Latest Filing)
- $24.4MReported Market Value (Latest Filing)
- 5.1%Portfolio Weight (% of 13F Equity Book)
- 61,387Quarter-over-Quarter Share Change
- -$17.6MQuarter-over-Quarter Value Change
- 814,994Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 22 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 121,877 | 61,387 | -33.5% | $24.4M | 5.1% | $200.0 |
| Q4 2025 | 183,264 | 20,400 | -10.0% | $42.0M | 9.2% | $229.1 |
| Q3 2025 | 203,664 | 32,300 | -13.7% | $32.8M | 8.6% | $161.0 |
| Q2 2025 | 235,964 | 43,800 | -15.7% | $39.9M | 9.8% | $168.9 |
| Q1 2025 | 279,764 | 60,000 | -17.7% | $39.6M | 10.3% | $141.4 |
| Q4 2024 | 339,764 | 91,550 | -21.2% | $53.8M | 13.2% | $158.3 |
| Q3 2024 | 431,314 | 42,800 | -9.0% | $54.8M | 10.6% | $127.0 |
| Q2 2024 | 474,114 | 158,600 | -25.1% | $51.3M | 9.2% | $108.3 |
| Q1 2024 | 632,714 | 58,148 | -8.4% | $57.9M | 11.0% | $91.5 |
| Q4 2023 | 690,862 | +95,168 | +16.0% | $43.3M | 8.8% | $62.6 |
| Q3 2023 | 595,694 | 0 | — | $26.4M | 5.8% | $44.3 |
| Q2 2023 | 595,694 | 189,200 | -24.1% | $29.0M | 5.4% | $48.7 |
| Q1 2023 | 784,894 | 30,100 | -3.7% | $43.6M | 8.5% | $55.5 |
| Q4 2022 | 814,994 | +219,000 | +36.7% | $32.7M | 7.6% | $40.2 |
| Q3 2022 | 595,994 | +25,000 | +4.4% | $26.1M | 6.0% | $43.8 |
| Q2 2022 | 570,994 | +123,500 | +27.6% | $20.2M | 4.7% | $35.4 |
| Q1 2022 | 447,494 | +235,800 | +111.4% | $18.2M | 4.5% | $40.7 |
| Q4 2021 | 211,694 | +47,200 | +28.7% | $19.8M | 4.8% | $93.4 |
| Q3 2021 | 164,494 | +1,300 | +0.8% | $18.3M | 5.8% | $111.4 |
| Q2 2021 | 163,194 | 5,200 | -3.1% | $18.5M | 6.4% | $113.5 |
| Q1 2021 | 168,394 | +89,794 | +114.2% | $17.1M | 6.9% | $101.5 |
| Q4 2020 | 78,600 | — | — | $7.8M | 5.0% | $99.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Eagle Health Investments LP first disclose a NTRA position in 13F-HR filings?
Eagle Health Investments LP first reported NATERA (NTRA) on its 13F-HR filing for the period ending 2020-12-31 (Q4 2020). The position has appeared on 22 reported quarters within Pactolio's tracked window.
What was Eagle Health Investments LP's most recent quarter-over-quarter share-count change in NTRA?
Between Q4 2025 and Q1 2026, Eagle Health Investments LP reduced its NTRA position by 61,387 shares (-33.5%), leaving 121,877 shares at a market value of $24.4M.
Does the implied price-per-share represent Eagle Health Investments LP's cost basis in NTRA?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.